• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Recursion Pharmaceuticals, Inc.

    Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers EXAI RXRX
    Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers EXAI RXRX
    Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion Announces Plans to Open New Office in London
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Tickers RXRX
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.